|
|
|
| Economic burden of patients with cervical cancer and precancerous lesions |
| LI Haitao1, WANG Yan2, SHEN Guqun2, YUAN Min2, LIU Liping3, LIU Guangchao1, ZHU Lin1
|
1. School of Public Health, Xinjiang Medical University, Urumqi, Xinjiang 830054, China;
2. Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China;
3. Tuoli County People's Hospital, Tuoli, Xinjiang 834500, China |
|
|
|
|
Abstract Objective To investigate the economic burden of cervical cancer and precancerous lesions, so as to provide the evidence for improving the management of cervical cancer and formulating the policies for reducing the economic burden of cervical cancer and precancerous lesions. Methods The hospitalized patients with cervical cancer and precancerous lesions were recruited from four hospitals in Xinjiang Uygur Autonomous Region from September 2020 to June 2021. The direct medical expenditures, direct non-medical expenditures, duration of absence from work in patients and their family members as carers were collected using a questionnaire designed by the Cancer Hospital of the Chinese Academy of Medical Sciences, and the economic burdens of cervical cancer and precancerous lesions were estimated. The factors affecting the economic burden of cervical cancer were identified using a multivariable linear regression model. Results Totally 265 patients with cervical cancer and precancerous lesions were included, with an average age of ( 49.80±10.07 ) years. There were 170 patients with cervical cancer, including 64 cases with stage I, 79 cases with stage II, and 27 cases with stages III/Ⅳ, and 95 patients with precancerous lesions, including 33 cases with low-grade squamous intraepithelial lesion ( LSIL ) and 62 cases with high-grade squamous intraepithelial lesion ( HSIL ). The median economic burdens (interquartile range) were 11 481 ( 4 523 ), 17 850 ( 9 096 ), 112 883 ( 59 623 ), 150 875 ( 105 206 ) and 197 842 ( 61 844 ) Yuan per patient among cases with LSIL, HSIL, and stage I, II and III/Ⅳ cervical cancer, respectively, among which the direct medical expenditures accounted for 85.89% to 93.86%. The median economic burdens (interquartile range) were 708 ( 1 711 ), 11 678 (6 590), 2 557 ( 19 472 ), and 14 943 ( 27 773 ) Yuan per patient with precancerous lesions, and were 910 (1 530), 105 770 ( 91 019 ), 39 765 ( 30 490 ), and 146 445 ( 123 039 ) Yuan per patient with cervical cancer during the diagnostic phase, the clinical treatment phase, the follow-up phase, and in total, respectively. Multivariable linear regression analysis results showed that pathological stage ( β'=0.202, P=0.003 ) and duration of hospital stay ( β'=0.695, P<0.001 ) correlated with the economic burden among patients with cervical cancer. Conclusion There is a high economic burden among patients with cervical cancer and precancerous lesions. Advanced pathological stage and long duration of hospital stay may increase the economic burden among cervical cancer patients.
|
|
Received: 02 December 2021
Revised: 12 January 2022
Published: 13 April 2022
|
|
|
|
|
|
[1] WU Q H,JIA M M,CHEN H M,et al. The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan Province,China:a retrospective case series study[J/OL]. PLoS One,2020,15(5)[2022-01-12].https://doi.org/10.1371/journal.pone.0232129.
[2] 夏昌发. 中国消除宫颈癌的最优策略和路径研究[D].北京:北京协和医学院,2021.
XIA C F.Optimal strategy and pathway towards cervical cancer elimination in China[D]. Beijing:Peking Union Medical College,2021.
[3] LI X,ZHENG R,LI X,et al.Trends of incidence rate and age at diagnosis for cervical cancer in China,from 2000 to 2014[J]. Chin J Cancer Res,2017,29(6):477-486.
[4] 陶思源,赵方辉,杨春霞,等. 子宫颈癌及癌前病变患者直接经济负担及其影响因素研究[J].中华预防医学杂志,2018,52(12):1281-1286.
TAO S Y,ZHAO F H,YANG C X,et al.Study on direct economic burden and influencing factors in patients with cervical cancer and precancerous lesions[J]. Chin J Prev Med,2018,52(12):1281-1286.
[5] RIGHOLT C H,PABLA G,MAHMUD S M.The direct medical costs of diseases associated with human papillomavirus infection in Manitoba,Canada[J]. Appl Health Econ Health Policy,2018,16(2):195-205.
[6] LÓPEZ N,Gil-DE-MIGUEL Á,PASCUAL-GARCÍA R,et al. Reduction in the burden of hospital admissions due to cervical disease from 2003-2014 in Spain[J]. Hum Vaccin Immunother,2018,14(4):917-923.
[7] 石菊芳,石春雷,岳馨培,等.1996—2014年中国恶性肿瘤经济负担的系统评价[J].中华肿瘤杂志,2016,38(12):929-941.
SHI J F,SHI C L,YUE X P,et al.Economic burden of cancer in China during 1996-2014:a systematic review[J].Chin J Oncol,2016,38(12):929-941.
[8] 乌鲁木齐市人民政府.2020年新疆城镇居民人均可支配收入34 838元,同比增长0.5%[EB/OL].(2021-01-28)[2022-01-12].http://www.urumqi.gov.cn/sy/zwxx/462068.htm.
[9] 陈猛,夏昌发,刘冰,等.中国子宫颈低级别鳞状上皮内病变患者经济负担分析[J].中国肿瘤,2021,30(11):827-833.
CHEN M,XIA C F,LIU B,et al.Economic burden of cervical low-grade squamous intraepithelial lesion in China[J].China Cancer,2021,30(11):827-833.
[10] 乔友林,赵宇倩.宫颈癌的流行病学现状和预防[J].中华妇幼临床医学杂志(电子版),2015,11(2):1-6.
QIAO Y L,ZAHO Y Q.Epidemiology and prevention of cervical cancer[J]. Chin J Obstet Gynecol Pediatr(Electron Ed),2015,11(2):1-6.
[11] 石丽丽,王小芳,杨丽萍,等.兰州市宫颈癌患者住院费用变化及影响因素研究[J].现代预防医学,2009,36(6):1029-1030.
SHI L L,WANG X F,YANG L P,et al.Analysis on the changes and the influential factors of hospitalization expenses of the patients with cervical cancer in Lanzhou city[J]. Mod Prev Med,2009,36(6): 1029-1030.
[12] 高菁,崔斌,朱兆芳,等.榆林市两家医院DRGs支付方式改革效果评价[J].中华医院管理杂志,2019,35(5):362-366.
GAO J,CUI B,ZHU Z F,et al.Evaluation of DRGs payment reform of two hospitals in Yulin[J].Chin J Hosp Adm,2019,35(5):362-366.
[13] 徐雪琴,方凤梅. 农村地区两种宫颈癌筛查方案应用效果比较[J]. 预防医学,2020,32(3):315-317.
XU X Q,FANG F M.Comparison of two cervical cancer screening programs in rural areas[J]. Prev Med,2020,32(3):315-317.
[14] 肖圆圆,武丽,缪华章,等.广东省两种宫颈癌筛查方案的检出率和费用分析[J].预防医学,2021,33(7):726-729.
XIAO Y Y,WU L,MIAO H Z,et al.Case detection rate and cost analysis of two cervical cancer screening programmes in Guangdong Province[J].Prev Med,2021,33(7):726-729.
[15] 缪之文,徐莉莉,张丽成,等.皮肤癌患者住院费用及影响因素的通径分析[J].中国卫生统计,2020,37(2):170-173.
MIAO Z W,XU L L,ZHANG L C,et al.Path analysis of hospitalization expenses and influencing factors in patients with skin cancer[J].Chin J Health Stat,2020,37(2):170-173. |
|
|
|
